Form 8-K - Current report:
SEC Accession No. 0001193125-21-248345
Filing Date
2021-08-17
Accepted
2021-08-17 07:00:56
Documents
12
Period of Report
2021-08-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d167957d8k.htm   iXBRL 8-K 23343
  Complete submission text file 0001193125-21-248345.txt   149522

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA gmtx-20210816.xsd EX-101.SCH 2909
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE gmtx-20210816_lab.xml EX-101.LAB 18887
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gmtx-20210816_pre.xml EX-101.PRE 11871
5 EXTRACTED XBRL INSTANCE DOCUMENT d167957d8k_htm.xml XML 3535
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

EIN.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 211180887
SIC: 2834 Pharmaceutical Preparations